Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
暂无分享，去创建一个
M. Tomasson | S. Iida | M. Mohty | A. Lesokhin | N. Raje | X. Leleu | E. Leip | A. Czibere | B. Arnulf | M. Raab | N. Bahlis | R. Niesvizky | H. Quach | A. Viqueira | S. Sullivan | P. Rodríguez-Otero